BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company's Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs

SUNNYVALE, Calif., May 5, 2021 -- (Healthcare Sales & Marketing Network) -- BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undrugga... Biopharmaceuticals, Oncology, Venture Capital BridGene Biosciences, IMTAC, chemoproteomic
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news